What is the Tatva Chintan Pharma Chem Ltd share price today?

The share price of NSE:TATVA-EQ on 01 Oct 2026 (as of 15:05:03 IST) is ₹1733.

What is the NSE:TATVA-EQ 52 week high low price?

Over the past 52 weeks (as of 01 Oct 2026), the NSE:TATVA-EQ 52 week high low range shows a high of ₹1880 and a low of ₹1003.

What is the Tatva Chintan Pharma Chem Ltd market cap?

As on 01 Oct 2026, Tatva Chintan Pharma Chem Ltd market cap is ₹41681100000.

What is the shareholding pattern of Tatva Chintan Pharma Chem Ltd Stock?

The shareholding pattern of Tatva Chintan Pharma Chem Ltd, as of last reported-on 30 Jun 2026 is: Promoters: 72.02% Foreign Institutional Investors (FII): 3.93% Domestic Institutional Investors (DII): 0.32% Mutual Funds: 2.79% Retail & Others: 20.94% This demonstrates an outstanding distribution of ownership.

What are the PE and PB ratios of Tatva Chintan Pharma Chem Ltd?

The Price-to-Earnings (PE) ratio of Tatva Chintan Pharma Chem Ltd is 81.1169, and the Price-to-Book (PB) ratio is 3.1445, as on 01 Oct 2026.

Tatva Chintan Pharma Chem Share Price

1637.10+0.00 (-1.49%)

+15.88% past 1 Year

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

1 Day

-1.49%

1 Week

-0.41%

1 Month

-9.00%

3 Month

-5.43%

6 Month

+21.09%

YTD

+22.70%

1 Year

+15.88%

5 Year

-41.09%

10 Year

Max

-22.48%

YTD

10Y

MAX

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

Price Analysis

1 Day

1 Week

1 Month

3 Months

6 Months

1 Year

Low

1621.10

1579.10

1525.50

1520.00

1101.00

1044.09

High

1699.00

2113.60

About

Tatva Chintan Pharma Chem Limited is a specialty chemicals manufacturing company engaged in the manufacture of a diverse portfolio of structure directing agents (SDAs), phase transfer catalysts (PTCs), electrolyte salts Read more

Chemicals

Smallcap

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats

1. Premium insight available after login

2. Sign in to view full SWOT analysis

3. Unlock strengths, weaknesses, opportunities & threats

QVT

Quality

0/100-

Valuation

0/100-

Technical

0/100-

Peer Stocks

1 week

1 month

1 year

Name

SOLARINDSNSE

PIDILITINDNSE

SRFNSE

FLUOROCHEMNSE

NAVINFLUORNSE

GODREJINDNSE

DEEPAKNTRNSE

AETHERNSE

FINEORGNSE

AARTIINDNSE

TATVANSE

LTP

1W Low

1W High

Market cap (₹)

19654+854 (4.54%)

18800

20880

1,75,629Cr

1510.9+49.3 (3.37%)

1400.20

1528.50

1,51,253Cr

2428.6+93.1 (3.99%)

2324.70

2428.60

71,142Cr

4463.9+215.7 (5.08%)

4175

4600

47,482Cr

8530-150 (-1.73%)

8242

8745

43,119Cr

952.55+47.65 (5.27%)

896

980.50

31,376Cr

1520.6+1.2 (0.08%)

1504.70

1615

20,842Cr

1501.1-115.1 (-7.12%)

1490.30

1692.40

20,181Cr

5089+40 (0.79%)

4919

5424

15,980Cr

439.15+3.4 (0.78%)

425.05

459.80

15,562Cr

1637.1-6.8 (-0.41%)

1579.10

1699

3,884Cr

Tatva Chintan Pharma Chem Share Price

1637.10+0.00 (-1.49%)

+15.88% past 1 Year

Financial overview

Compounded Sales Growth

10 years-

5 years11%

3 years6%

Last year32%

Compounded Profit Growth

10 years-

5 years-4%

3 years-3%

Last year636%

Stock Price CAGR

10 years-

5 years-10%

3 years5%

1 year16%

Return on Equity

10 years19%

5 years10%

3 years4%

Last year6%

CAGR%

Sales

Profits

Returns

ROE

10Y	5Y	3Y	TTM
-	11%	6%	32%
-	-4%	-3%	636%
-	-10%	5%	16%
19%	10%	4%	6%

Peer Comparison

Symbol

SOLARINDS

PIDILITIND

SRF

FLUOROCHEM

NAVINFLUOR

GODREJIND

DEEPAKNTR

AETHER

FINEORG

AARTIIND

TATVA

Price	M.Cap (₹)	PE Ratio	EPS (₹)	EV/EBITDA	Annual PAT
19,654	₹175629 Cr	88.19	72.11	250.42	₹1678 Cr
1,510.9	₹151253 Cr	56.35	6.03	30.24	₹2449 Cr
2,428.6	₹71142 Cr	31.17	17.18	106.98	₹1835 Cr
4,463.9	₹47482 Cr	77.21	20.09	90.49	₹577 Cr
8,530	₹43119 Cr	47.35	52.48	208.91	₹664 Cr
952.55	₹31376 Cr	26.69	8.44	50.37	₹1241 Cr
1,520.6	₹20842 Cr	19.62	29.15	96.58	₹551 Cr
1,501.1	₹20181 Cr	80.97	5.12	24.71	₹219 Cr
5,089	₹15980 Cr	33.18	49.62	176.69	₹417 Cr
439.15	₹15562 Cr	26.2	4.67	29.86	₹419 Cr
1,637.1	₹3884 Cr	61.73	9.17	44.08	₹42 Cr

Profit & Loss

Consolidated

Standalone

Quarterly

Yearly

₹

Name

Net Revenue

Other Income

Total Revenue

Total Expenditure

Operating Profit

Interest Expense

PBT

Net Profit

Sep 2026	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022	Dec 2021	Sep 2021	Jun 2021	Mar 2021	Dec 2020	Sep 2020	Jun 2020
₹217 Cr	₹167 Cr	₹134 Cr	₹131 Cr	₹124 Cr	₹117 Cr	₹108 Cr	₹86 Cr	₹83 Cr	₹105 Cr	₹98 Cr	₹84 Cr	₹97 Cr	₹114 Cr	₹125 Cr	₹121 Cr	₹90 Cr	₹88 Cr	₹99 Cr	₹105 Cr	₹124 Cr	₹107 Cr	₹109 Cr	₹80 Cr	₹60 Cr	₹52 Cr
₹2 Cr	₹3 Cr	-₹35 L	₹2 Cr	₹1 Cr	₹1 Cr	₹72 L	₹4 L	₹38 L	₹1 Cr	₹5 Cr	₹1 Cr	₹76 L	₹1 Cr	₹85 L	₹1 Cr	₹2 Cr	₹2 Cr	₹31 L	₹5 Cr	₹3 Cr	₹3 Cr	₹3 Cr	₹66 L	₹2 Cr	₹17 L
₹219 Cr	₹170 Cr	₹134 Cr	₹133 Cr	₹125 Cr	₹118 Cr	₹109 Cr	₹86 Cr	₹84 Cr	₹107 Cr	₹103 Cr	₹85 Cr	₹97 Cr	₹115 Cr	₹125 Cr	₹122 Cr	₹92 Cr	₹90 Cr	₹99 Cr	₹109 Cr	₹127 Cr	₹110 Cr	₹111 Cr	₹81 Cr	₹62 Cr	₹52 Cr
₹187 Cr	₹145 Cr	₹116 Cr	₹115 Cr	₹110 Cr	₹109 Cr	₹106 Cr	₹86 Cr	₹85 Cr	₹100 Cr	₹89 Cr	₹80 Cr	₹83 Cr	₹99 Cr	₹111 Cr	₹105 Cr	₹81 Cr	₹76 Cr	₹79 Cr	₹83 Cr	₹90 Cr	₹83 Cr	₹86 Cr	₹57 Cr	₹55 Cr	₹43 Cr
₹42 Cr	₹35 Cr	₹28 Cr	₹27 Cr	₹23 Cr	₹18 Cr	₹10 Cr	₹7 Cr	₹6 Cr	₹14 Cr	₹20 Cr	₹12 Cr	₹21 Cr	₹22 Cr	₹17 Cr	₹19 Cr	₹13 Cr	₹17 Cr	₹22 Cr	₹29 Cr	₹39 Cr	₹29 Cr	₹27 Cr	₹25 Cr	₹8 Cr	₹11 Cr
₹3 Cr	₹2 Cr	₹1 Cr	₹49 L	₹51 L	₹41 L	₹39 L	₹42 L	₹17 L	₹31 L	₹21 L	₹38 L	₹3 Cr	₹3 Cr	₹3 Cr	₹2 Cr	₹2 Cr	₹1 Cr	₹1 Cr	₹99 L	₹1 Cr	₹3 Cr	₹1 Cr	₹1 Cr	₹99 L	₹50 L
₹29 Cr	₹21 Cr	₹17 Cr	₹18 Cr	₹14 Cr	₹9 Cr	₹2 Cr	-₹24 L	-₹1 Cr	₹7 Cr	₹14 Cr	₹5 Cr	₹11 Cr	₹13 Cr	₹8 Cr	₹14 Cr	₹9 Cr	₹14 Cr	₹19 Cr	₹25 Cr	₹35 Cr	₹24 Cr	₹24 Cr	₹22 Cr	₹6 Cr	₹8 Cr
₹21 Cr	₹16 Cr	₹10 Cr	₹15 Cr	₹10 Cr	₹7 Cr	₹1 Cr	₹14 L	-₹66 L	₹5 Cr	₹10 Cr	₹3 Cr	₹8 Cr	₹10 Cr	₹17 Cr	₹12 Cr	₹7 Cr	₹10 Cr	₹18 Cr	₹23 Cr	₹32 Cr	₹23 Cr	₹21 Cr	₹21 Cr	₹4 Cr	₹7 Cr

Balance Sheet

Consolidated

Standalone

₹

Name

Equity And Liabilities

Share Capital

Total Reserves

Reserve excluding Revaluation Reserve

Shareholder's Funds

Secured Loans

Deferred Tax Assets / Liabilities

Other Long Term Liabilities

Long Term Provisions

Total Non-Current Liabilities

Current Liabilities

Trade Payables

Other Current Liabilities

Short Term Borrowings

Short Term Provisions

Total Current Liabilities

Total Liabilities

Contingent Liabilities

Total Debt

Assets

Gross Block

Less Accumulated Depreciation

Net Block

Capital Work in Progress

Non Current Investments

Long Term Investment

Long Term Loans & Advances

Other Non Current Assets

Total Non-Current Assets

Current Assets Loans & Advances

Currents Investments

Inventories

Sundry Debtors

Cash and Bank

Other Current Assets

Short Term Loans and Advances

Total Current Assets

Net Current Assets (Including Current Investments)

Total Assets

Book Value

Adjusted Book Value

Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018
—	—	—	—	—	—	—	—	—
₹23 Cr	₹23 Cr	₹23 Cr	₹22 Cr	₹22 Cr	₹20 Cr	₹8 Cr	₹8 Cr	₹8 Cr
₹758 Cr	₹715 Cr	₹714 Cr	₹493 Cr	₹451 Cr	₹146 Cr	₹110 Cr	₹72 Cr	₹54 Cr
₹758 Cr	₹715 Cr	₹714 Cr	₹493 Cr	₹451 Cr	₹146 Cr	₹110 Cr	₹72 Cr	₹54 Cr
₹782 Cr	₹739 Cr	₹737 Cr	₹515 Cr	₹473 Cr	₹166 Cr	₹118 Cr	₹80 Cr	₹62 Cr
₹5 Cr	₹0	₹64 L	₹4 Cr	₹13 Cr	₹27 Cr	₹39 Cr	₹32 Cr	₹20 Cr
-₹10 Cr	-₹13 Cr	-₹12 Cr	-₹16 Cr	-₹9 Cr	₹2 Cr	₹4 Cr	₹3 Cr	₹2 Cr
₹1 Cr	₹0	₹0	₹0	₹80,000	₹1 Cr	₹3 L	₹4 L	₹52 L
₹3 Cr	₹1 Cr	₹1 Cr	₹1 Cr	₹65 L	₹55 L	₹40 L	₹29 L	₹0
-₹77 L	-₹11 Cr	-₹10 Cr	-₹11 Cr	₹5 Cr	₹31 Cr	₹44 Cr	₹35 Cr	₹22 Cr
—	—	—	—	—	—	—	—	—
₹58 Cr	₹33 Cr	₹45 Cr	₹32 Cr	₹45 Cr	₹47 Cr	₹32 Cr	₹22 Cr	₹25 Cr
₹40 Cr	₹25 Cr	₹24 Cr	₹50 Cr	₹33 Cr	₹21 Cr	₹15 Cr	₹11 Cr	₹2 Cr
₹114 Cr	₹36 Cr	₹10 Cr	₹156 Cr	₹92 Cr	₹49 Cr	₹40 Cr	₹40 Cr	₹36 Cr
₹87 L	₹3 Cr	₹56 L	₹2 Cr	₹1 Cr	₹11 Cr	₹6 L	₹4 L	₹0
₹213 Cr	₹96 Cr	₹80 Cr	₹241 Cr	₹171 Cr	₹128 Cr	₹88 Cr	₹73 Cr	₹63 Cr
₹994 Cr	₹824 Cr	₹807 Cr	₹744 Cr	₹649 Cr	₹325 Cr	₹249 Cr	₹188 Cr	₹147 Cr
₹12 Cr	₹7 Cr	₹6 Cr	₹1 Cr	₹3 Cr	₹51 L	₹68 L	₹43 L	₹0
₹120 Cr	₹36 Cr	₹14 Cr	₹170 Cr	₹120 Cr	₹90 Cr	₹91 Cr	₹77 Cr	₹56 Cr
—	—	—	—	—	—	—	—	—
₹733 Cr	₹617 Cr	₹488 Cr	₹232 Cr	₹186 Cr	₹139 Cr	₹122 Cr	₹73 Cr	₹70 Cr
₹123 Cr	₹89 Cr	₹61 Cr	₹36 Cr	₹27 Cr	₹18 Cr	₹11 Cr	₹7 Cr	₹13 Cr
₹609 Cr	₹529 Cr	₹427 Cr	₹196 Cr	₹160 Cr	₹120 Cr	₹111 Cr	₹67 Cr	₹56 Cr
₹23 Cr	₹22 Cr	₹73 Cr	₹231 Cr	₹51 Cr	₹10 Cr	₹5 Cr	₹6 Cr	₹10 Cr
₹4 Cr	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹47 L
₹4 Cr	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹47 L
₹5 Cr	₹4 Cr	₹4 Cr	₹3 Cr	₹2 Cr	₹30 L	₹17 L	₹38 L	₹17 L
₹2 Cr	₹1 Cr	₹83 L	₹55 L	₹51 L	₹0	₹0	₹0	₹0
₹645 Cr	₹558 Cr	₹509 Cr	₹430 Cr	₹214 Cr	₹131 Cr	₹116 Cr	₹73 Cr	₹67 Cr
—	—	—	—	—	—	—	—	—
₹0	₹0	₹10 Cr	₹0	₹0	₹0	₹0	₹0	₹50 L
₹196 Cr	₹134 Cr	₹153 Cr	₹162 Cr	₹170 Cr	₹72 Cr	₹64 Cr	₹36 Cr	₹29 Cr
₹119 Cr	₹90 Cr	₹70 Cr	₹84 Cr	₹57 Cr	₹91 Cr	₹50 Cr	₹41 Cr	₹32 Cr
₹9 Cr	₹14 Cr	₹38 Cr	₹45 Cr	₹177 Cr	₹5 Cr	₹11 Cr	₹16 Cr	₹9 Cr
₹8 Cr	₹6 Cr	₹7 Cr	₹5 Cr	₹5 Cr	₹6 Cr	₹3 Cr	₹4 Cr	₹1 Cr
₹18 Cr	₹21 Cr	₹20 Cr	₹17 Cr	₹27 Cr	₹20 Cr	₹6 Cr	₹18 Cr	₹9 Cr
₹350 Cr	₹265 Cr	₹298 Cr	₹314 Cr	₹436 Cr	₹195 Cr	₹133 Cr	₹114 Cr	₹80 Cr
₹136 Cr	₹169 Cr	₹218 Cr	₹74 Cr	₹264 Cr	₹66 Cr	₹45 Cr	₹42 Cr	₹18 Cr
₹994 Cr	₹824 Cr	₹807 Cr	₹744 Cr	₹649 Cr	₹325 Cr	₹249 Cr	₹188 Cr	₹147 Cr
₹334	₹316	₹315	₹232	₹213	₹83	₹146	₹99	₹77
₹334	₹316	₹315	₹232	₹213	₹83	₹59	₹40	₹31

Cash Flow

Consolidated

Standalone

₹

Name

Profit Before Tax

Adjustment

Changes In working Capital

Cash Flow after changes in Working Capital

Cash Flow from Operating Activities

Cash Flow from Investing Activities

Cash Flow from Financing Activitie

Net Cash Inflow / Outflow

Opening Cash & Cash Equivalents

Effect of Foreign Exchange Fluctuations

Closing Cash & Cash Equivalent

Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018
₹57 Cr	₹8 Cr	₹44 Cr	₹45 Cr	₹104 Cr	₹61 Cr	₹48 Cr	₹27 Cr	₹0
₹44 Cr	₹29 Cr	₹29 Cr	₹17 Cr	₹12 Cr	₹7 Cr	₹9 Cr	₹8 Cr	₹0
-₹62 Cr	-₹8 Cr	₹34 Cr	-₹24 Cr	-₹77 Cr	-₹38 Cr	-₹23 Cr	-₹22 Cr	₹0
₹39 Cr	₹29 Cr	₹107 Cr	₹37 Cr	₹39 Cr	₹30 Cr	₹34 Cr	₹13 Cr	₹0
₹31 Cr	₹25 Cr	₹98 Cr	₹28 Cr	₹20 Cr	₹20 Cr	₹25 Cr	₹7 Cr	₹0
-₹116 Cr	-₹65 Cr	-₹121 Cr	-₹101 Cr	-₹197 Cr	-₹21 Cr	-₹40 Cr	-₹17 Cr	₹0
₹79 Cr	₹17 Cr	₹31 Cr	₹38 Cr	₹235 Cr	-₹5 Cr	₹10 Cr	₹17 Cr	₹0
-₹5 Cr	-₹24 Cr	₹8 Cr	-₹36 Cr	₹59 Cr	-₹6 Cr	-₹5 Cr	₹8 Cr	₹0
₹11 Cr	₹35 Cr	₹27 Cr	₹63 Cr	₹4 Cr	₹10 Cr	₹16 Cr	₹8 Cr	₹0
-₹19 L	₹9 L	-₹8 L	-₹9 L	-₹2 L	₹0	₹0	₹0	₹0
₹6 Cr	₹11 Cr	₹35 Cr	₹27 Cr	₹63 Cr	₹4 Cr	₹11 Cr	₹16 Cr	₹0

Fundamental Ratios

Consolidated

Standalone

No results found

Tatva Chintan Pharma Chem Share Price

1637.10+0.00 (-1.49%)

+15.88% past 1 Year

Shareholding summary

Promoters

72.02%

FII

4.38%

DII

0.34%

2.87%

Others

20.39%

Promoters

FII

DII

Others

Quarterly

Yearly

Shareholding Pattern

Quarterly

Yearly

Name

Promoters

FII

DII - Others

DII - MFs

Retail & Others

Sep 2026	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025
72.02%	72.02%	72.02%	72.02%	72.02%	72.02%
4.38%	3.93%	3.81%	4.17%	3.40%	3.26%
0.34%	0.32%	0.12%	0.07%	0.05%	0.04%
2.87%	2.79%	2.87%	3.25%	3.82%	5.07%
20.39%	20.94%	21.18%	20.49%	20.71%	19.61%

Bulk & block deals

Name

Graviton Research Capital Llp

Musigma Securities

Graviton Research Capital Llp

Musigma Securities

Graviton Research Capital Llp

Musigma Securities

Graviton Research Capital Llp

Deal Date	Action	Deal Value	Deal Price	Qty Traded	Deal Type	%Stake Traded	Exchange
15 Oct 2025	Purchase	16.19 Cr	₹1,210.89	1.34 L	Bulk	0.571599	NSE
15 Oct 2025	Purchase	18.14 Cr	₹1,262.14	1.44 L	Bulk	0.614383	NSE
15 Oct 2025	Sell	18.14 Cr	₹1,262.51	1.44 L	Bulk	0.614383	NSE
15 Oct 2025	Sell	16.22 Cr	₹1,212.74	1.34 L	Bulk	0.571599	NSE
25 Jul 2025	Purchase	13.80 Cr	₹1,170.74	1.18 L	Bulk	0.50373	NSE
25 Jul 2025	Purchase	25.01 Cr	₹1,152.08	2.17 L	Bulk	0.927946	NSE
25 Jul 2025	Sell	13.80 Cr	₹1,171.36	1.18 L	Bulk	0.50373	NSE
25 Jul 2025	Sell	25.05 Cr	₹1,153.92	2.17 L	Bulk	0.927946	NSE
18 Jul 2025	Purchase	13.20 Cr	₹1,035.16	1.28 L	Bulk	0.545321	NSE
18 Jul 2025	Sell	13.21 Cr	₹1,035.79	1.28 L	Bulk	0.545321	NSE

Insider trading & SAST

Client name

Ajay Mansukhlal Patel & Pacs

Ajay Patel

Ajay Mansukhlal Patel Huf

Ajay Patel

Ajay Mansukhlal Patel

Ajay Mansukhlal Patel (Huf)

Nippon India Mutual Fund

Ajay Mansukhlal Patel Huf

Darshana Nitinkumar Shah

Shekhar Rasiklal Somani

Reported on	Client category	Action	%Stake traded	Holding % post deal	Deal price	Qty traded	Deal period	Deal mode	Post transaction holding	Insider/SAST	Regulation type	Security type
18 Feb 2026	Promoter	Acquisition	3.06	20.16	—	7.15 L	06 Feb 2026	Dissolution Of Huf	47,15,345	SAST	29(2)	—
18 Feb 2026	Other	Acquisition	3.06	—	—	7.15 L	06 Feb 2026	-	—	SAST	10(6)	—
18 Feb 2026	Promoter	Disposal	3.06	—	—	7.15 L	06 Feb 2026	Dissolution Of Huf	—	SAST	29(2)	—
13 Feb 2026	Promoter	Acquisition	3.06	—	—	7.15 L	06 Feb 2026	—	—	SAST	10(5)	—
09 Feb 2026	Promoter & Director	Acquisition	3.058062	20.16	—	7.15 L	06 Feb 2026	Inter-se Transfer	47,15,345	Insider Trading	—	Equity Shares
09 Feb 2026	Promoter Group	Disposal	3.058062	0	—	7.15 L	06 Feb 2026	Inter-se Transfer	0	Insider Trading	—	Equity Shares
22 Jul 2025	Other	Disposal	0.12	3.16	—	28.61 K	04 Jul 2023 - 03 Jul 2025	Market	7,40,251	SAST	29(2)	—
13 Sep 2023	Promoter	Disposal	0.88	3.05	—	2.06 L	06 Sep 2023	Market	7,15,345	SAST	29(2)	—
13 Sep 2023	Promoter	Disposal	0.99	0.16	—	2.34 L	06 Sep 2023	Market	39,628	SAST	29(2)	—
13 Sep 2023	Promoter	Disposal	0.99	23.07	—	2.34 L	06 Sep 2023	Market	53,96,861	SAST	29(2)	—

Tatva Chintan Pharma Chem Share Price

Price Analysis

Share Price Live Stats

Share Market Cap & Key Ratios Overview

About

Stock Analysis (SWOT)

QVT

Peer Stocks

Tatva Chintan Pharma Chem Share Price

Tatva Chintan Pharma Chem Share Price

Financial overview

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Peer Comparison

Profit & Loss

Balance Sheet

Cash Flow

Fundamental Ratios

Tatva Chintan Pharma Chem Share Price

Tatva Chintan Pharma Chem Share Price

Oscillators

Moving averages

Tatva Chintan Pharma Chem Share Price

Shareholding summary

Shareholding Pattern

Bulk & block deals

Insider trading & SAST

Tatva Chintan Pharma Chem Share Price

Corporate Actions

Company details

Tatva Chintan Pharma Chem Share Price

Corporate filings & documents

Announcements

Annual reports

Concalls & investor presentations

Tatva Chintan Pharma Chem Share Price

News

Tatva Chintan Q2 EBITDA Rises Strongly With Improved Operating Margin

Tatva Chintan Pharma Chem Reports Strong Second Quarter Profit Growth

Tatva Chintan reports strong second quarter revenue growth year on year

Tatva Chintan Pharma Chem schedules investor and analyst meetings for September 23

Tatva Chintan Pharma Chem to hold analyst and investor meet on 15 September

Tatva Chintan approves Rs 200 crore greenfield capex for specialty chemicals

Tatva Chintan Pharma Chem posts strong Q1 EBITDA growth and margin expansion

Tatva Chintan Pharma Chem Q1 profit and revenue surge strongly year-on-year

Tatva Chintan Pharma - Quaterly Results

Tatva Chintan Pharma Chem reports sharp YoY expansion in Q4 EBITDA and margin

Tatva Chintan Pharma Chem Q4 profit surges on strong revenue growth

Tatva Chintan Pharma reports Profit after tax of 9.02 Crores, in the March 2026 quarter

Tatva Chintan Pharma Chem informs about analyst meet

Tatva Chintan Pharma Chem Faces 80% Natural Gas Supply Cap Under Government Order 2026.

Tatva Chintan Pharma Chem informs about disclosure

Tatva Chintan Pharma Chem informs about newspaper publication

Tatva Chintan Pharma Chem Guides Agro and Pharma Intermediates Revenue Growth for 2027

Tatva Chintan Pharma Chem Guides Electrolyte Salts to 7-8% Revenue Share by CY2026 from 1%.

Tatva Chintan Pharma Chem Announces Jolva Greenfield Capex and Execution Timeline

Tatva Chintan Pharma Chem Guides EBITDA Margins to 20-22% Range in FY27

Tatva Chintan Pharma Chem Ltd Share Price Today

Tatva Chintan Pharma Chem Quick Links

Other Stocks

Calculators

Brokerage Calculator

Stock Average Calculator

MTF Calculator

Margin Calculator

Span Margin Calculator